Skip to main content
OpenTrials
Completed

NCT Number: NCT00882336

European Study of Cardiovascular Risk

The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.

The patient's participation consists of a single study visit during a routine visit of the patient to the clinic/office.

Study variables will be measured:

* By an interview between physician and patient during the visit and/or available medical records' information: social and demographic patient characteristics, relevant family medical history, current medication. * By questions asked to the physician: physician perception of patients' CV risk factor, guidelines adherence and cost-containment. * By measurement performed to the patient during the visit: weight, height, BMI, waist and hip circumference will be measured. * CV risk factors (blood parameters) will be measured by collecting available data documented within the last year in the medical records and by the collection and analyses of a blood sample during the visit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Risk Factors Behavior Body Weight Cardiovascular Diseases Diabetes Diabetes Mellitus Dyslipidemias Endocrine System Diseases Glucose Metabolism Disorders Hyperlipidemia Hyperlipidemias Hypertension Lipid Metabolism Disorders Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Smoking Vascular Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Alland, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of informed consent.
  • Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalisation for a CV event) from Primary Care or hospital outpatient clinic.

Exclusion criteria

  • Subjects who are unwilling or unable to provide informed consent
  • Previous CV disease event or hospitalisation for a CV event
  • Current participation in a clinical trial

Treatment and study plan

Primary outcomes

  1. LDL-cholesterol, systolic and diastolic blood pressure, Tot. cholesterol, Non-HDL cholesterol, HDL-cholesterol, waist and hip circumference, HbA1c

    Time frame: Cross-sectional

  2. Gender, age, patients with diabetes and/or hypertension (%), smoker status, family medical history.

    Time frame: Cross-sectional

Secondary outcomes

  1. BMI, Score based 10 year CHD mortality > 5%, High Risk patients (no. and %)

    Time frame: Cross-sectional

  2. Use of concomitant medication: anticoagulant, anti hypertensive, antidiabetic, lipid-lowering drugs

    Time frame: Cross-sectional

  3. Biomarkers: Apo-A1, Apo-B, Hs-CRP, Creatinine, albuminuria, uric acid, glomerular filtration rate.

    Time frame: Cross-sectional

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Epidemiological Study of European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice

Acronym: EURIKA

Important dates

Study start
2009
Study completion
2009
First posted
Apr 16, 2009
Registry last updated
Oct 29, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.